The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lilly's 2013 sales performance.
an entirely new treatment category for these patients – and a whole new revenue stream for AZ as it chases after SGLT2 market leader Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim. ... Those trials are due to read out next year.
There are some encouraging signs with other drugs however, including mid-stage clinical results with Incyte/Eli Lilly’s Olumiant (baricitinib), Johnson &Johnson’s IL-12/IL-23 inhibitor Stelara (ustekinumab)
New indication boosts $1bn+ hopes for this year. Eli Lilly’s Taltz can now compete on a level playing field with Novartis’ rival drug Cosentyx, after picking up a third FDA ... mobility, according to Lilly, which says only 15% of patients with the
to be one of a range of suitable treatments, including Cosentyx (secukinumab) and Lilly’s Talz (ixekizumab), then the least expensive should be chosen, once administration costs, dosage, price per dose
Garraway joins from Eli Lilly. Roche’s chief medical officer and head of global product development, Sandra Horning, will retire later this year after five years in the role. ... Prior to joining Lilly in 2017, Garraway was director of the Joint Centre
[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...